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Abstract  
Background: Human milk is known to be the best nutrition for infants as it provides many health benefits. For 
non-breastfed infants, cow's milk based infant formula is the most optimal option to provide the needed 
nutrition. However, approximately 2-5% of all formula-fed infants experience cow’s milk allergy during their 
first year of life. Partially hydrolyzed whey formula (pHF-W) have been widely recommended to prevent the 
development of allergic disease in infants. However, according to epidemiological data, approximately half of 
the infants developing allergy are not part of the at-risk group. 
Objectives and Methods: This article aims to review the effects of pHF-W in preventing allergy, especially 
atopic disease, in all non-breastfed infants, as well as the safety aspect of pHF-W if used as routine formula. 
The role of pHF-W in the management of functional gastro-intestinal (GI) disorders is also reviewed. 
Results: Several clinical studies showed that pHF-W decrease the number of infants with eczema. The 
strongest evidence is provided by the 15-year follow up of the German Infant Nutritional Intervention study 
which showed reduction in the cumulative incidence of eczema and allergic rhinitis in pHF-W (OR 0.75, 95% CI 
0.59-0.96 for eczema; OR 0.67, 95% CI 0.47-0.95 for allergic rhinitis) and casein extensively hydrolysed formula  
group (OR 0.60, 95% CI 0.46-0.77 for eczema; OR 0.59, 95% CI 0.41-0.84 for allergic rhinitis), compared to CMF 
as a control, after 15 years of follow-up. pHF-W was also found to be beneficial in the management of 
functional GI disorders such as regurgitation, constipation and colic.  
Conclusions: The use of pHF-W in allergic infants has been recommended in various guidelines across the 
countries, as a primary prevention of allergic disease. One pHF-W has been approved by the US FDA and the 
European Commission's European Food Safety Authority (EFSA) for its safety and suitability as a routine infant 
formula for all healthy infants. According to the data obtained in the management of functional GI disorders, 
pHF-W is better tolerated than formula with intact protein. Further studies assessing the effect of routine use 
of pHF-W in a larger population of non-breastfed infants should also be conducted, in order to observe any 
potential harm and to determine the benefit and cost-effectiveness ratio. 







Human breast milk is known to be the best nutrition 
for infants. Breast milk is found to provide 
protection for the children against infection and 
malocclusion, as well as improve the intelligence. 
Growing evidence also suggests that breastfeeding 
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might protect against overweight and diabetes later 
in life.1 
Nevertheless, due to various circumstances, a 
large proportion of infants cannot receive human 
milk.1,2 Globally, only 38% of the infants are found 
to be exclusively breastfed.2 For nonbreastfed 
infants, infant formula is the most optimal option to 
provide the needed nutrition. Infant formula is 
usually prepared from industrially modified cow’s 
milk and processed to adjust the nutritional content 
according to the needs of infants. However, as cow’s 
milk proteins constitute the most common food 
allergens in infants, cow’s milk formula is one of the 
most frequent causes of food allergy in infants.3,4 
Approximately 2-5% of all formula-fed infants 
experience cow’s milk allergy during their first year 
of life.5,6 Cow’s milk allergy (CMA) is often 
associated with manifestations in various organ 
systems, such as gastrointestinal, respiratory tract, 
and skin. CMA may cause failure to thrive and even 
sometimes cause life-threatening anaphylactic 
reactions.5,7 In order to reduce the allergenic 
potential, cow’s milk protein in the infant formulas 
can be modified by hydrolyzation processes to 
reduce the size of the peptides, and therefore could 
induce tolerance without sensitization.3,4 
Hydrolyzed formulas (HF), according to clinical 
studies, may give beneficial effects in reducing the 
risk of several allergic diseases, especially infants 
born in families with atopic disease (high-risk 
infants). Several reports have recommended the use 
of HF for the at-risk infants. 8-10 Of all HFs available, 
the partially hydrolyzed whey formula (pHF-W) 
have been widely recommended to prevent the 
development of allergies in infants.13-16 However, 
according to epidemiological data, approximately 
half of the infants developing allergy are not part of 
the at-risk group. This is because the number of 
infants in the non-at-risk group is significantly larger 
than that in the at-risk group.11 The infants in non-
at-risk group have approximately 15% risk of 
developing allergies.12 
Therefore, this article aims to evaluate and 
review the effects of pHF-W in preventing allergies, 
especially atopic diseases, in all non-breastfed 
infants, both the high-risk and non-at-risk infants, as 
well as the safety aspect of pHF-W to be used as a 
routine formula. 
 
Partially hydrolyzed whey formula (pHF-W) 
 
Milk proteins consist of two fractions: casein and 
whey. Casein is the coagulum portion of milk, which 
becomes clots or curds inside the stomach. It 
contains the larger and more complex protein 
molecules, which are harder to digest. Casein 
protein also contains more allergenic proteins, 
which are responsible for the majority of milk 
allergies. On the other hand, whey is the liquid 
portion of milk, which makes it easier to digest. It 
also contains less allergenic proteins. From this 
standpoint, the casein protein is considered to be 
more likely to trigger allergies or general indigestion 
than the whey protein.2,17 
The composition of casein and whey in cow’s 
milk is different from that in human breast milk. 
Cow’s milk protein is 77% casein and 23% whey, 
meanwhile breast milk protein is approximately 
30% casein and 70% whey, even though the 
casein/whey ratio in breast milk may fluctuate 
between 70/30 and 80/20 in early lactation and 
decrease to 50/50 in late lactation.2 Other than that, 
the whey and casein proteins in cow’s milk and 
breast milk might also differ in fraction number, 
amino acid composition, as well as the peptide 
mappings. Therefore, raw cow’s milk must be 
processed and modified to resemble the human 
breast milk composition before it is considered safe 
for infant consumption.2  
Hydrolyzed formulas (HFs) are typically derived 
from cow’s milk proteins, either whey or casein, 
which have undergone several procedures to 
breakdown these natural proteins into lower 
molecular-weight peptides. These protein 
modification procedures may include heating, ultra-
filtration, and enzymatic cleavage. Depending on the 
degree of hydrolysis and modification, the 
hydrolyzed cow’s milk formulas can be 
differentiated into partially hydrolyzed formula 
(pHF), of which the molecular weight is 3-10 kDA, 
and extensively hydrolyzed formulas (eHF), of 
which the molecular weight is <3 kDa. Compared to 
the nonhydrolyzed (intact) formula with the 
molecular weight of 14-68 kDA, hydrolyzed 
formula have lower molecular weight peptides, 
which are thought to induce oral tolerance without 
causing sensitization. Thus, hydrolyzed formula is 
thought to reduce the risk of allergic disease 
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compared to the intact formula.3,4 
The allergy-preventing property of hydrolyzed 
formula, however, seems to not only depend on the 
degree of hydrolisation but also on the method of 
hydrolisation, as well as other factors. The 
qualitative changes of the peptides due to the 
hydrolysis process may also affect the potential 
benefit of the formula. There are at least three factors 
affecting the allergy-preventing effect of a 
hydrolyzed formula, which are the protein source 
(whey and casein), method of hydrolysis 
(temperature, pH, and the type of enzyme used), and 
the degree of hydrolysis.  
Due to these reasons, it is safe to say that every 
HF is different and might even have contradictory 
characteristics from one to another, even with the 
same degree of hydrolysis. Nutten  et al also 
confirms this statement. They studied the 
physicochemical profile of 76 commercially 
available whey- and casein-based eHF (eHF-W and 
eHF-C) products and found significant variability in 
the molecular weight profile of the peptides, amino 
acid components, as well as the allergenicity of the 
products, which would eventually affect the 
effectiveness of each product in preventing 
allergies.18 Researches studying the effect of HFs 
should, therefore, evaluate every HFs individually. 
Pooling together various hydrolysates (HFs) would 
be inappropriate, as it may cause bias and the results 
could not represent any of the individual HFs.3,4  
Partially hydrolyzed whey formula (pHF-W) is 
one of the partially hydrolyzed formulas composed 
of 100% whey protein. pHF-W has been 
demonstrated to result in positive effects on 
preventing the development of allergies, particularly 
atopic dermatitis, in infants.13-16 As yet, only one 
routine infant pHF-W has been granted a qualified 
health claim by the U.S. Food and Drug 
Administration for risk reduction of atopic 
dermatitis.4,19 The following sections discuss the 
current evidences found regarding the effect of pHF-
W in preventing atopic disease, as well as the 
possibility of pHF-W to be used as a routine 
formula. 
 
pHF-W and prevention of atopic disease 
 
Atopic diseases are a group of diseases caused by an 
exaggerated IgE immune response to otherwise 
harmless allergens.20 Pediatric atopic disease may 
include atopic dermatitis (eczema), asthma, allergic 
rhinitis, as well as food allergy. International Study 
of Asthma and Allergies in Childhood (ISAAC) 
reported a significant increase in the worldwide 
prevalence of pediatric atopic diseases in both 
developed and developing countries. Approximately 
8% of children aged less than 3 years are affected by 
food allergy, meanwhile the prevalence of children 
with eczema is  estimated to be as high as 30%.21,22  
In general, the development of allergy is influenced 
by several factors, which are the genetic 
predisposition, allergen exposure (including time, 
dose, frequency of exposure, processing and 
consumption of food proteins such as hydrolysate, 
gastro-intestinal microbiome, LCPUFAs), and other 
contributing factors (such as cesarean section at 
birth, early exposure to antibiotics, seasonal 
variations, pollution, passive smoking, 
industrialization, pets at home, infections, lifestyle, 
and vitamin D). In order to prevent the development 
of allergic disease, current guidelines recommend 
several preventive measures, which include no 
maternal food restriction during pregnancy and 
lactation, exclusive breastfeeding for the first 4-6 
months of life of the infants, timing of introduction 
of the complementary foods, and also the use of HFs 
with demonstrated efficacy when breastfeeding is 
not possible.9 
The partially hydrolyzed whey formula (pHF-W) 
has been observed clinically to decrease the number 
of infants with eczema. Several  studies have 
assessed the effectiveness of initial exposure to 
pHF-W to reduce the risk of eczema. Two different 
meta-analyzes published in 2010 showed that 
healthy infants with a family history of allergies who 
are fed with pHF-W have a lower risk of  atopic 
dermatitis compared to babies who are fed the intact 
cow's milk protein formula (CMF). Subanalysis 
conducted in the meta-analyses showed that the risk 
reduction of eczema was approximately 52 and 55%, 
respectively, at the age of 12 months, and 
approximately 38 and 36%, respectively, at that age 
of >30 months.3,23,24  
Baumgartner reported that the number of  infants 
who developed atopic symptoms if fed a pHF-W 
was only 25% of those fed CMF (OR 0.25, 95% CI 
0.18-0.36).24 The analysis  also showed that the 
effect of pHF-W in reducing the allergic 
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manifestations is equivalent to breast milk, 
especially for long-term prevention.25 A literature 
review of 8 clinical trials also confirmed that pHF-
W supports normal growth in infants, and showed 
that the risk of atopic dermatitis in infants who are 
not fully breastfed in the general population also 
decreases after administration of specific pHF-W, 
compared to CMF, in the first 4-6 months of life.26 
The strongest evidence is provided by the 15-year 
follow up of the German Infant Nutritional 
Intervention (GINI) study, which studied the effect 
of pHF-W, eHF-W, and eHF-C in 2,252 
participants, compared to CMF as the control, in 
reducing the cumulative incidence and prevalence of 
pediatric allergic diseases. The result showed that 
there was reduction in the cumulative incidence of 
eczema and allergic rhinitis in pHF-W (OR 0.75, 
95% CI 0.59-0.96 for eczema; OR 0.67, 95% CI 
0.47-0.95 for allergic rhinitis) and eHF-C groups 
(OR 0.60, 95% CI 0.46-0.77 for eczema; OR 0.59, 
95% CI 0.41-0.84 for allergic rhinitis), compared to 
CMF as a control, after 15 years of follow-up.27  
While the above studies showed positive effect of 
pHF-W for preventing allergies, several other 
studies showed contradictory results with other HFs. 
Several issues and weaknesses, however, are found 
in the methodology of each study that needs to be 
taken into account.13,28-30 The common issue is that 
these meta-analysis  pool together different types of 
pHF from multiple manufacturers, which would 
give rise to different characteristics of the resulting 
peptides. Hence, the results of these studies might 
not be useful, as the collective results could not 
represent any of the protein hydrolysate.3,4 
Systematic review and meta-analysis by Boyle 
found no consistent evidence that both pHF, not only 
limited to pHF-W, and eHF can reduce the risk of 
allergies or autoimmune outcomes in babies with a 
high risk of allergies. This might be due to the 
inclusion criteria of this study, which included 
multiple interventions and retrospective cohort 
studies, excluded 7 pHF interventional studies, as 
well as the unusual segmentation of age (0-4 years, 
compared to other meta-analyses in which the 
segmentations were at 0-1 year).28 
A randomized-controlled trial (RCT) by Boyle 
analyzed the use of pHF and prebiotic 
supplementation, compared to standard formulas, in 
preventing eczema in high-risk infants. The results 
showed that there was no difference in incident of 
eczema between the intervention of pHF+prebiotic 
and standard formula in high-risk infants within 12 
months of follow-up. This might be due to  the 
methodology, such as the use of different  pHF and 
the randomization process which was performed at 
the age of <1 month (not at birth), which could lead 
to biased results.29 
A Cochrane meta-analysis by Osborn also stated 
that there is no evidence that pHF provides positive 
effect in preventing allergies, compared to exclusive 
breastfeeding. However, the analysis of the studies 
performed in preterm and term infants were 
combined. Other than that, the study also analyzed 
different types of pHFs, which could cause the 
findings of this meta-analysis to be considered 
invalid, as different pHFs might exhibit different 
effect on preventing allergies.30  
The RCT by Lowe et al13 also revealed that pHF-
W could not reduce the risk of allergic 
manifestations, compared to standard formulas. 
However, some weaknesses were also found in the 
methodology of the study as; the end point was 
conducted by telephone interview, only 50% of 
infants received formula at 4 months of age, 16.5% 
never received the allocated formula, and that the 
study was single blind.  
 
pHF-W for all non-breastfed infants: safety 
aspects 
 
The use of pHF, including pHF-W, in allergic 
infants has been recommended in various guidelines 
across the countries, as a primary prevention of 
allergic disease, mainly atopic dermatitis, in high-
risk infants.8-10 However, the compliance rates for 
these guidelines are relatively low. The Pouessel et 
al31 study in 2006 revealed that there are still around 
50% of children born with genetic risk not given 
hydrolyzed formulas, including pHF-W, as a form 
of prevention. The 2008 ASCIA annual meeting also 
concluded that in practice, guidelines were not 
followed, and in fact only 2.5% of children born 
with genetic risk were given a hydrolyzed formula.8 
Although the use of pHF-W has been 
recommended for at-risk infants,13-16 The fact is that 
half of all infants who develop allergies are not part 
of the at-risk group, as mentioned above. This is 
because the number of infants in the non-risk group 
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is significantly larger than the number of infants in 
the risk group.11 Therefore, it is under debate on 
whether pHF-W should be considered as a routine 
formula for all nonbreastfed infants, regardless of 
their risk of allergies.4 
One pHF-W has been approved by the US FDA and 
the European Commission's European Food Safety 
Authority (EFSA) for its safety and suitability as a 
routine infant formula for all healthy infants, 
regardless of its relationship to its use in preventing 
allergies.20,33 In terms of nutritional content, pHF-W 
is very similar to CMF, except that the protein 
content in several pHF-Ws is slightly higher than in 
CMF. This makes pHF-W also meets all nutrient 
requirements as required for standard CMF.6 pHF-
W typically contains 67 kcal/100 mL of energy, 11.2 
g/100 kcal of carbohydrate, 5.1 g/100 kcal of fat, 
with the protein content varied in the range of 1.8-
2.2 g/100 kcal. Meanwhile, CMF contains 67 
kcal/100 mL of energy, 11 g/100 kcal of 
carbohydrate, 5.3 g/100 kcal of fat, and 1.8 g/100 
kcal of protein.33,34  
Based on limited data of the long-term effect of 
pHF-W in healthy infants, it was found that there 
was no significant difference between the growth of 
pHF-W infants and CMF infants.27 For the long-
term use, Rzehak et al found no significant 
differences between the BMI trajectory in the pHF-
W group, extensively hydrolyzed whey formula 
(eHF-W), CMF, and breast milk groups after 6 years 
of follow-up. In fact, it was found that pHF-W 
shows the closest growth rate to breast milk, among 
the other infant formula.35 In another study, the Z-
score trajectories showed that the weight gain in 
pHF infants is normative, despite the accelerated 
weight gain in CMF infants.36 A systematic review 
and expert consensus also concluded that pHF-W 
was as safe as CMF in terms of supporting normal 
development. There was no difference found in the 
nutritional value and safety of pHF-W compared to 
CMF.37  
Data regarding the effects of pHF-W in hormonal 
response and metabolism of healthy infants were 
also limited. Hoppe et al reported that whey protein 
increased fasting insulin by 21% (p=0.006) in young 
boys aged 8 years in 7 days, with no change in IGF-
1 (p=0.27), suggesting an increase in insulin 
resistance. This would naturally arise concern that 
pHF-W may induce the development of diabetes 
mellitus.38 However, as to anticipate this concern, 
the FDA-approved pHF-W has undergone the 
process of removing the caseino-Glyco-
MacroPeptide (cGMP), resulting in the formation of 
modified sweet whey (MSW) formula.34 This 
formula is found to have lower plasma level of a 
number of amino acids, such as leucine, isoleucine, 
threonine, and valine, which are considered to be 
insulin secretagogues (insulinogenic amino acids). 
This formula would, therefore, lead to a reduced risk 
of developing diabetes, compared to the classical 
pHF-W.34,39 It was also found that the administration 
of pHF, including pHF-W, in infants with a genetic 
risk of developing type 1 diabetes mellitus did not 
increase incidence of type 1 diabetes.40 
 
pHF and functional gastro-intestinal disorders  
 
Functional gastro-intestinal disorders (FGIDs) 
FGIDs are a frequent cause of parental concern and 
consequent impaired infants and relatives’ quality of 
life, and impose a financial burden to health care, 
insurance and families.41 Management of these 
FGIDs should focus on improving both infants 
symptoms and family quality of life. If more than 
parental reassurance is needed, available evidence 
suggests that nutritional advice is recommended as 
it is effective and most of the time devoid of adverse 
effects.  
Troublesome regurgitation occurs in about 25 % 
of all infants and usually improves spontaneously 
within the first year after birth.42 A thickened pHF-
W was reported to be more effective than a 
thickened formula with intact protein.43  
Infant colic is reported to occur in about 20 % of 
all infants.42 Frequent and extensive auto-
medication by parents of infants with colic has been 
reported.44,45 Therefore, management should focus 
on sustaining parents to cope with their child’s 
excessive crying and distressed behavior  by 
informing the parents that in general crying peaks at 
about four to six weeks after birth, may last up to 
three hours per day in otherwise normal infants and 
steadily diminishes from 12 weeks onwards.46 In 
formula fed infants, when CMPA is an unlikely 
diagnosis, a partial hydrolysate with prebiotics and 
beta-palmitate; or a synbiotic formula with reduced 
lactose and partially hydrolyzed protein may be 
beneficial.47 
 
World.Nutr.Journal | 58  
Functional constipation occurs in about 10% of 
all infants.42 A pHF-W, (a mixture of) prebiotics, 
probiotics, synbiotcs, and beta-palmitate and/or a 
formula with high magnesium content (but within 
normal ranges) may offer some benefit.41 
pHF-W has also been shown to have some beneficial 
effect on functional GI manifestations, such as 
regurgitation and constipation.9 A review by 
Vandenplas et al. showed that there was a significant 
decrease in the number of regurgitation events per 
day with the use of pHF-W. In addition, stool in the 
infants group with pHF-W was also found to be 
softer compared to stool in the standard formula33,43  
and soy-based formulas.43 Other data also showed 
that the use of pHF-W in non-breastfed infants can 
accelerate gastric emptying, reduce the incidence of 
infantile colic, and other functional gastrointestinal 




Breast milk is still the best nutrition for babies. In 
nonbreastfed infants, CMF can provide adequate 
nutrition to support normal growth and 
development. However, CMF is known to often 
induce cow's milk allergic reaction. In a large-scale 
GINI study and several other studies, pHF-W has 
been proven as a formula which is superior in 
reducing atopic disease and has been recommended 
in several guidelines to prevent atopic disease in 
high-risk group infants. Even so, more large-scale 
clinical studies replicating these studies, particularly 
GINI study, might be needed to confirm the 
effectiveness of pHF-W. 
As the number of infants developing allergy is 
greater in the non-at-risk group compared to the at-
risk group, the use of pHF-W should not be limited 
to the at-risk group only. Despite some reported 
differences in studies, pHF-W has always shown 
superior benefits among all the available infant 
formulas, with minimal potential harm for healthy 
term infants. According to a comparative 
pharmacoeconomic analysis, pHF-W is also 
superior over the standard formula in the aspect of 
family and societal perspectives, as well as the 
attractive cost-effectiveness.47 Further studies 
assessing the effect of routine use of pHF-W in a 
larger population of nonbreastfed infants should also 
be conducted, in order to observe any potential harm 
and to determine the benefit and cost-effectiveness 
ratio. 
 
Conflict of Interest 
 





This article is distributed under the terms of the  
Creative Commons Attribution 4.0 International 
Licence 
(http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons 




1.  Victora CG, Bahl R, Barros AJD, França GVA, Horton 
S, Krasevec J, et al. Breastfeeding in the 21st century: 
epidemiology, mechanisms, and lifelong effect. Lancet. 
2016;387(10017):475–90.  
2.  Martin C, Ling P-R, Blackburn G. Review of infant 
feeding: key features of breast milk and infant formula. 
Nutrients]. 2016;8(5):279. 
3.  Cabana MD. The role of hydrolyzed formula in allergy 
prevention. Ann Nutr Metab. 2017;70(2):38–45.  
4.  Vandenplas Y, Munasir Z, Hegar B, Kumarawati D, 
Suryawan A. A perspective on partially hydrolyzed 
protein infant formula in nonexclusively breastfed 
infants. Korean J Pediatr 2019;62(5):149–54.  
5.  Koletzko S, Niggemann B, Arato A, Dias JA, 
Heuschkel R, Husby S, et al. Diagnostic approach and 
management of cowʼs-milk protein allergy in infants 
and children. J Pediatr Gastroenterol Nutr. 
2012;55(2):221–9.  
6.  Vandenplas Y. Prevention and management of cow’s 
milk allergy in non-exclusively breastfed Infants. 
Nutrients. 2017;9(7):731.  
7.  von Berg A. Modified proteins in allergy prevention. In: 
Microbial host-interaction: tolerance versus allergy. 
Nestle Nutr Workshop Ser Pediatr Program. 
2009;64:239-47.  
8.  Joshi PA, Smith J, Vale S, Campbell DE. The 
Australasian Society of Clinical Immunology and 
Allergy infant feeding for allergy prevention guidelines. 
Med J Aust. 2019;210(2):89-93.   
9.  Fleischer DM, Venter C, Vandenplas Y. Hydrolyzed 
formula for every infant? Nestle Nutr Inst Workshop 
Ser. 2016;86:51-65.   
10.  Chan ES, Cummings C. Dietary exposures and allergy 
 
World.Nutr.Journal | 59  
prevention in high-risk infants. Paediatr Child Health. 
2013;18(10):545–9.  
11.  Halken S. Prevention of allergic disease in childhood: 
clinical and epidemiological aspects of primary and 
secondary allergy prevention. Pediatr Allergy Immunol. 
2004;15(s16):9–32.  
12.  Exl BM, Deland U, Secretin M-C, Preysch U, Wall M, 
Shmerling DH. Improved general health status in an 
unselected infant population following an allergen 
reduced dietary intervention programme The ZUFF-
STUDY-PROGRAMME. Eur J Nutr. 2000;39(3):89–
102.  
13.  Lowe AJ, Hosking CS, Bennett CM, Allen KJ, Axelrad 
C, Carlin JB, et al. Effect of a partially hydrolyzed whey 
infant formula at weaning on risk of allergic disease in 
high-risk children: A randomized controlled trial. J 
Allergy Clin Immunol. 2011;128(2):360-365.e4.  
14.  Prescott SL, Tang ML. The Australasian Society of 
Clinical Immunology and Allergy position statement: 
summary of allergy prevention in children. Med J Aust. 
2005;182(9):464–7.  
15.  Heine RG, Tang ML. Dietary approaches to the 
prevention of food allergy. Curr Opin Clin Nutr Metab 
Care. 2008;11(3):320–8.  
16.  Pali-Schöll I, Renz H, Jensen-Jarolim E. Update on 
allergies in pregnancy, lactation, and early childhood. J 
Allergy Clin Immunol. 2009;123(5):1012–21.  
17.  Wal JM. Cow’s milk proteins/allergens. Ann Allergy, 
Asthma Immunol. 2002;89(6 Suppl1):3–10.   
18.  Nutten S, Maynard F, Järvi A, Rytz A, Simons PJ, 
Heine RG, et al. Peptide size profile and residual 
immunogenic milk protein or peptide content in 
extensively hydrolyzed infant formulas. Allergy. 
2020;75(6):1446-9..  
19.  Chung CS, Yamini S, Trumbo PR. FDA’s Health Claim 
Review: Whey-protein partially hydrolyzed infant 
formula and atopic dermatitis. Pediatrics 
2012;130(2):e408–14.  
20.  Moreno MA. Atopic diseases in children. JAMA 
Pediatr. 2016;170(1):96.  
21.  Asher MI, Montefort S, Björkstén B, Lai CK, Strachan 
DP, Weiland SK, et al. Worldwide time trends in the 
prevalence of symptoms of asthma, allergic 
rhinoconjunctivitis, and eczema in childhood: ISAAC 
Phases One and Three repeat multicountry cross-
sectional surveys. Lancet. 2006;368(9537):733–43.  
22.  Al-Herz W. A systematic review of the prevalence of 
atopic diseases in children on the Arabian peninsula. 
Med Princ Pract. 2018;27(5):436–42.  
23.  Szajewska H, Horvath A. Meta-analysis of the evidence 
for a partially hydrolyzed 100% whey formula for the 
prevention of allergic diseases. Curr Med Res Opin. 
2010;26(2):423–37.  
24.  Alexander DD, Cabana MD. Partially hydrolyzed 100% 
whey protein infant formula and reduced risk of atopic 
dermatitis: a meta-analysis. J Pediatr Gastroenterol 
Nutr. 2010;50(4):1.  
25.  Baumgartner M, Brown CA, Exl B-M, Secretin M-C, 
van’t Hof M, Haschke F. Controlled trials investigating 
the use of one partially hydrolyzed whey formula for 
dietary prevention of atopic manifestations until 60 
months of age: An overview using meta-analytical 
techniques. Nutr Res. 1998;18(8):1425–42.  
26.  Sauser J, Nutten S, de Groot N, Pecquet S, Simon D, 
Simon H-U, et al. Partially hydrolyzed whey infant 
formula: literature review on effects on growth and the 
risk of developing atopic dermatitis in infants from the 
general population. Int Arch Allergy Immunol. 
2018;177(2):123–34.  
27.  von Berg A, Filipiak-Pittroff B, Schulz H, Hoffmann U, 
Link E, Sußmann M, et al. Allergic manifestation 15 
years after early intervention with hydrolyzed formulas 
- the GINI Study. Allergy. 2016;71(2):210–9.  
28.  Boyle RJ, Ierodiakonou D, Khan T, Chivinge J, 
Robinson Z, Geoghegan N, et al. Hydrolysed formula 
and risk of allergic or autoimmune disease: systematic 
review and meta-analysis. BMJ. 2016;352:974.  
29.  Boyle RJ, Tang MLK, Chiang WC, Chua MC, Ismail I, 
Nauta A, et al. Prebiotic-supplemented partially 
hydrolysed cow’s milk formula for the prevention of 
eczema in high-risk infants: a randomized controlled 
trial. Allergy. 2016;71(5):701–10.  
30.  Osborn DA, Sinn JKH, Jones LJ. Infant formulas 
containing hydrolysed protein for prevention of allergic 
disease. Cochrane Database Syst Rev. 2018; 
10(10):CD003664.  
31.  Pouessel G, Michaud L, Guimber D, Mention K, 
Gottrand F, Turck D. Adherence to guidelines for the 
primary prevention of food allergy. Ital J Pediatr. 
2006;32:333–7.  
32.  Scientific Opinion on the essential composition of 
infant and follow-on formulae. EFSA J. 2014 
Jul;12(7):3760.  
33.  Czerkies LA, Kineman BD, Cohen SS, Reichert H, 
Carvalho RS. A Pooled analysis of growth and 
tolerance of infants exclusively fed partially hydrolyzed 
whey or intact protein-based infant formulas. Int J 
Pediatr. 2018; 2018:4969576.  
34.  Macé K, Steenhout P, Klassen P, Donnet A. Protein 
quality and quantity in cow’s milk-based formula for 
healthy term infants: past, present and future. In: Protein 
and energy requirements in infancy and childhood. 
Nestle Nutr Workshop Ser Pediatr Program. 
2006;58:189-203  
35.  Rzehak P, Sausenthaler S, Koletzko S, Reinhardt D, von 
Berg A, Krämer U, et al. Short- and long-term effects 
of feeding hydrolyzed protein infant formulas on 
growth at ≤6 y of age: results from the German Infant 
Nutritional Intervention Study. Am J Clin Nutr. 
2009;89(6):1846–56.  
36.  Mennella JA, Ventura AK, Beauchamp GK. 
Differential growth patterns among healthy infants fed 
protein hydrolysate or cow-milk formulas. Pediatrics. 
2011;127(1):110–8.  
37.  Vandenplas Y, Latiff AHA, Fleischer DM, Gutiérrez-
Castrellón P, Miqdady M-IS, Smith PK, et al. Partially 
hydrolyzed formula in non-exclusively breastfed 
infants: A systematic review and expert consensus. 
 
World.Nutr.Journal | 60  
Nutrition. 2019;57:268–74.  
38.  Hoppe C, Mølgaard C, Dalum C, Vaag A, Michaelsen 
KF. Differential effects of casein versus whey on 
fasting plasma levels of insulin, IGF-1 and IGF-
1/IGFBP-3: results from a randomized 7-day 
supplementation study in prepubertal boys. Eur J Clin 
Nutr. 2009;63(9):1076–83.  
39.  Salehi A, Gunnerud U, Muhammed SJ, Östman E, Holst 
JJ, Björck I, et al. The insulinogenic effect of whey 
protein is partially mediated by a direct effect of amino 
acids and GIP on β-cells. Nutr Metab. 2012;9(1):48.  
40.  Hummel S, Beyerlein A, Tamura R, Uusitalo U, Andrén 
Aronsson C, Yang J, et al. First infant formula type and 
risk of islet autoimmunity in the environmental 
determinants of diabetes in the young (TEDDY) study. 
Diabetes Care. 2017;40(3):398–404.  
41.  Vandenplas Y, Hauser B, Salvatore S. Functional 
Gastrointestinal Disorders in Infancy: Impact on the 
Health of the Infant and Family.  Pediatr Gastroenterol 
Hepatol Nutr. 2019;22(3):207-216. 
42.  Vandenplas Y, Abkari A, Bellaiche M, Benninga MA, 
Chouraqui JP, Çokura FC, et al. Prevalence and health 
Outcomes of functional gastrointestinal symptoms in 
infants from birth to 12 months of age J Pediatr 
Gastroenterol Nutr. 2015;61(5):531-7.  
43.  Vandenplas Y, Leluyer B, Cazaubiel M, Housez B, 
Bocquet A. Double-blind comparative trial with 2 
antiregurgitation formulae J Pediatr Gastroenterol Nutr. 
2013;57(3):389-93..   
44.  Oshikoya KA, Senbanjo IO, Njokanma OF. Self-
medication for infants with colic in Lagos, Nigeria. 
BMC Pediatr. 2009;9:9. 
45.  Headley J, Northstone K. Medication administered to 
children from 0 to 7.5 years in the Avon Longitudinal 
Study of Parents and Children (ALSPAC). Eur J Clin 
Pharmacol. 2007;(63):189-95.  
46.  Vandenplas Y, Gutierrez-Castrellon P, Velasco-Benitez 
C, Palacios J, Jaen D, Ribeiro H, et al. Practical 
algorithms for managing common gastrointestinal 
symptoms in infants. Nutrition. 2013;29:184-94.  
47.  Xinias I, Analitis A, Mavroudi A, Roilides I, 
Lykogeorgou M, Delivoria V, et al. Innovative dietary 
intervention answers to baby colic. Pediatr 
Gastroenterol Hepatol Nutr. 2017;20:00-6. 
 
 
 
 
 
 
